Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session on the role of subcutaneous tocilizumab in managing rheumatoid arthritis.
Immunological pathways play a crucial role in disease management, especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
Tocilizumab is a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody basically administered through intravenous infusion every 4 weeks. The treatment has been approved for patients with rheumatoid arthritis.
Due to the low risk of immunogenicity, the flexibility of IV and SC administration, and the convenience of administering weekly once, tocilizumab provides an effective treatment for severe, active, and progressive RA in adults.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
New protein target discovered for childhood medulloblastomas
2.
The New Canadian Guidelines for Drinking at High Risk, AUD.
3.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
4.
Study finds 81% of cancer cures touted by TikTok videos are fake
5.
Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?
1.
The Mysterious World of Petechiae: Exploring Causes and Treatments
2.
How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review
3.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
4.
Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy
5.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
Navigating the Complexities of Ph Negative ALL - Part IX
3.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
4.
Should We Use DARA Up Front As First-Line Therapy in MM?
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation